Specialty biopharmaceutical company RedHill Biopharma Ltd. (Nasdaq:RDHL) announced on Monday that the Biomedical Advanced Research and Development Authority (BARDA) selected its drug opaganib for development to treat Ebola virus disease.
BARDA will partially fund the advancement of opaganib under a cost-sharing contract to help combat Ebola outbreaks. Opaganib has shown progress through the Animal Rule pathway, enabling potential FDA approval using pivotal animal studies when human trials are not feasible.
In a U.S. Army study, opaganib significantly increased survival in an in vivo Ebola model, marking it as the first host-directed molecule to show activity against the virus. Recent studies also demonstrated a synergistic effect when combined with remdesivir, enhancing potency while maintaining cell viability. Opaganib is being developed for several other indications, including oncology, viral infections and COVID-19.
Federal funds from the Department of Health and Human Services support the project under contract number 75A50124C00059.
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date